Merger and Acquisition Activity Expectations in the Pharmaceutical Industry - 2012–2013 : Survey Snapshot

Document Sample
Merger and Acquisition Activity Expectations in the Pharmaceutical Industry   - 2012–2013 : Survey Snapshot Powered By Docstoc
					                                Pharmaceutical
                                       Survey Snapshot




Merger and Acquisition Activity
Expectations in the Pharmaceutical
Industry - 2012–2013: Survey Snapshot

Reference code: SR432SS

Published: June 2012


ICD Research

John Carpenter House
7 Carmelite Street
London EC4Y 0BS
United Kingdom
Tel: +44 (0) 20 7936 6400
Fax: +44 (0) 20 7336 6813
Website: www.icd-research.com




                                    www.icd-research.com
 TABLE OF CONTENTS



TABLE OF CONTENTS

1      Introduction ........................................................................................................................... 5
    1.1 What is This Report About? ............................................................................................................. 5
    1.2 Definitions ........................................................................................................................................ 5
    1.3 Methodology .................................................................................................................................... 6
    1.4 Profile of Survey Respondents: Global Pharmaceutical Industry ...................................................... 8
        1.4.1     Profile of buyer respondents: global pharmaceutical industry .................................................................... 8
        1.4.2     Profile of supplier respondents: global pharmaceutical industry ................................................................ 9
2      M&A Activity Projections in the Global Pharmaceutical Industry ................................... 11
    2.1 M&A activity projections in the global pharmaceutical industry by buyers ........................................11
    2.2 M&A activity projections in the global pharmaceutical industry by suppliers ....................................15
    2.3 M&A activity projections in the global pharmaceutical industry by region ........................................17
    2.4 M&A activity projections in the global pharmaceutical industry by company turnover ......................18
    2.5 Global pharmaceutical industry: expansion abroad vs M&A activity projections ..............................19
3      Appendix .............................................................................................................................. 20
    3.1 Global Pharmaceutical Industry Survey Results – Closed Questions ..............................................20
    3.2 Methodology ...................................................................................................................................35
    3.3 Contact us .......................................................................................................................................35
    3.4 About ICD Research .......................................................................................................................35
    3.5 Disclaimer .......................................................................................................................................35




Merger and Acquisition Activity Expectations in the Pharmaceutical Industry - 2012–2013:
                                                                                                                                                      Page 2
Survey Snapshot

© ICD Research. This product is licensed and is not to be photocopied                                                                 Published: June 2012
 TABLE OF CONTENTS



LIST OF FIGURES

Figure 1: M&A Projections: Global Pharmaceutical Manufacturers(%), 2010–2012 ............................................................................................ 13
Figure 2: M&A Projections: Global CRO and CMO Industry (%), 2010–2012 ...................................................................................................... 14
Figure 3: M&A Projections: Global Pharmaceutical Industry Suppliers (%), 2010–2012 ...................................................................................... 16
Figure 4: Global Pharmaceutical Industry M&A Projections by Region (%), 2012 ............................................................................................... 17
Figure 5: Global Pharmaceutical Industry M&A Projections by Turnover (%), 2012 ............................................................................................ 18
Figure 6: Global Pharmaceutical Industry: Expand Abroad vs M&A Activity Projections (%), 2012 ..................................................................... 19




Merger and Acquisition Activity Expectations in the Pharmaceutical Industry - 2012–2013:
                                                                                                                                                                        Page 3
Survey Snapshot

© ICD Research. This product is licensed and is not to be photocopied                                                                                 Published: June 2012
  TABLE OF CONTENTS



LIST OF TABLES

Table 1: Total Global Pharmaceutical Industry Survey Respondents by Company Type, 2012 ............................................................................. 8
Table 2: Global Pharmaceutical Industry Buyer Respondents by Job Role (%), 2012 ........................................................................................... 9
Table 3: Global Pharmaceutical Industry Buyer Respondents by Company Turnover (%), 2012 ........................................................................... 9
Table 4: Global Pharmaceutical Industry Buyer Respondents by Region (%), 2012 .............................................................................................. 9
Table 5: Global Pharmaceutical Industry Supplier Respondents by Job Role (%), 2012 ..................................................................................... 10
Table 6: Global Pharmaceutical Industry Supplier Respondents by Company Turnover (%), 2012 ..................................................................... 10
Table 7: Global Pharmaceutical Industry Supplier Respondents by Region (%), 2012 ........................................................................................ 10
Table 8: M&A Projections: Global Pharmaceutical Manufacturers(%), 2010–2012 ............................................................................................. 12
Table 9: M&A Projections: Global CRO and CMO (%), 2010–2012 .................................................................................................................... 14
Table 10: M&A Projections: Global Pharmaceutical Industry Suppliers (%), 2010–2012 ..................................................................................... 16
Table 11: Global Pharmaceutical Industry M&A Projections by Region (%), 2012 .............................................................................................. 17
Table 12: Global Pharmaceutical Industry M&A Projections by Turnover (%), 2012............................................................................................ 18
Table 13: Global Pharmaceutical Industry: Expand Abroad vs M&A Activity Projections (%), 2012 ..................................................................... 19
Table 14: Survey Results - Closed Questions ..................................................................................................................................................... 20




Merger and Acquisition Activity Expectations in the Pharmaceutical Industry - 2012–2013:
                                                                                                                                                                                            Page 4
Survey Snapshot

© ICD Research. This product is licensed and is not to be photocopied                                                                                                    Published: June 2012
 INTRODUCTION


1 Introduction

1.1 What is This Report About?

        This report is the result of an extensive survey drawn from ICD Research’s exclusive panel of leading
        pharmaceutical industry companies. As numerous countries recover from the effects of recession, this report
        provides the reader with a definitive analysis of industry outlook and explores how opportunities and demand
        are set to change in 2012–2013. Further, this report not only grants access to the opinions and strategies of
        business decision makers and competitors, but also examines their actions concerning business priorities.

        The report also examines:
          Revenue growth expectations: projects revenue growth expectations of major industry stakeholders
          Market-specific growth opportunities: identifies top growth regions in order that companies can allocate
          their marketing activities and budgets effectively
          Mergers and acquisitions: expectations surrounding merger and acquisition activity and core influencing
          factors
          Leading business concerns: identifies leading business concerns and subsequent efforts to negate them
          Procurement expenditure trends: tracks the procurement budgets of buyer companies and forecasts the
          possible change in spend.
          Factors for supplier selection: understands critical factors influencing supplier selection


1.2 Definitions

          Active pharmaceutical ingredients (API): An active ingredient (AI) is the substance in a pharmaceutical
          drug or a pesticide that is biologically active.

          Excipient: An excipient is generally a pharmacologically inactive substance used as a carrier for the active
          ingredients of a medication.

          Patent: It is a set of exclusive rights granted by a state (national government) to an inventor or their
          assignee for a limited period of time in exchange for a public disclosure of an invention.

          Contract manufacturing organization (CMO): CMO is an organization that serves the pharmaceutical
          industry and provides clients with comprehensive services such as drug development and manufacturing.
          Services offered by CMOs include, but are not limited to: pre-formulation, formulation development, stability
          studies, method development, pre-clinical and Phase I clinical trial materials, late-stage clinical trial
          materials, formal stability, scale-up, registration batches and commercial production.

          Contract research organization (CRO): Also called a clinical research organization, a CRO is a service
          organization that provides support to the pharmaceutical and bio-technology industries in the form of
          outsourced pharmaceutical research services, for both drugs and medical devices. CROs range from large,
          international full service organizations to small, niche specialty groups and can offer their clients the
          experience of moving a new drug or device from its conception to FDA/EMA marketing approval without the
          drug sponsor having to maintain a staff for these services


Merger and Acquisition Activity Expectations in the Pharmaceutical Industry - 2012–2013:
                                                                                                                     Page 5
Survey Snapshot

© ICD Research. This product is licensed and is not to be photocopied                                   Published: June 2012
 INTRODUCTION


          Company turnover: Companies with turnover of less than US$100 million are identified in the report as
          small companies. Companies with turnover between US$100 million–US$1 billion are referred to as medium
          sized companies and those with turnover of more than US$1 billion as large companies.

          E-procurement (electronic procurement): business-to-business (B2B) buying and selling of services
          through the internet and other IT solutions, such as electronic data interchange (EDI) and enterprise
          resource planning (ERP).

1.3 Methodology

        1) Online Survey

        The research source in this report is based on the surveyed opinions and forward-looking expectations of
        highly engaged and senior industry professionals. ICD Research conducted an extensive online survey during
        December 2011 taken by 247 senior global industry buyers and suppliers. These respondents cover C-levels,
        directors, managers and technical and professional staff.

        These respondents are drawn from the ICD Research Industry Insight Panel, an exclusive industry panel
        covering over two million business professionals worldwide. Respondents represent a dedicated professional
        community where participants are surveyed ‘in context’, drawn from our industry magazine and media
        communities, including the readership of Pharmaceutical Business Review and pharmaceutical-technology
        and delegate relationships across our global industry conference and forum events. These busines
				
DOCUMENT INFO
Description: Synopsis • Analysis of opinions drawn from leading pharmaceutical industry executives. • Analysis of Merger and Acquisition (M&A) activity in global pharmaceutical industry. Summary This report is the result of an extensive survey drawn from ICD Research’s exclusive panel of leading pharmaceutical industry executives. In this report, executives provide their future projections in terms of mergers and acquisitions. Scope • The opinions and forward looking statements of 247 industry executives have been captured in our in-depth survey, of which 51% represent Director and C-level respondents. • The research is based on primary survey research conducted by ICD Research accessing its B2B panels comprised of senior purchase decision makers and leading supplier organizations. • The geographical scope of the research is global – drawing on the activity and expectations of leading industry players across the Americas, Europe, Asia-Pacific, Africa and Middle East. • This report covers data and analysis on M&A activity of global pharmaceutical companies. Reasons To Buy • This report will help you to understand M&A activity projections in the global pharmaceuticals industry from buyers and suppliers point of view. • This report will help you to understand M&A activity projections in the global pharmaceuticals industry by region. • This report will help you to understand M&A activity projections in the global pharmaceuticals industry by company turnover. • This report will help you to understand M&A activity projections in the global pharmaceuticals industry by purchasing decision authority.
BUY THIS DOCUMENT NOW PRICE: $325 100% MONEY BACK GUARANTEED
PARTNER ICD Research
With emphasis on Insight, Consultancy and Delivery, iCD Research is a full-service, online market research agency. iCD Research is able to take advantage of all of the efficiencies and benefits that the Internet brings to offer proven research methodologies with fast turnaround and accurate results. iCD Research specialises in qualitative research for large finance, media, retail and entertainment clients. Market leaders in online focus groups, iCD Research has unleashed the full scale of the Internet to run focus groups across the globe for its major institutional clients. Utilising its sister organisation, The iD Factor, iCD Research also delivers strong quantitative research, ranging from ongoing consumer confidence studies through to consumer surveys throughout Europe and Asia. With its roots firmly in research, iCD Research doesn’t limit itself to only utilising online methods as the philosophy at the company is to match the methodology to the respondent. Yet the scale and speed of online research give iCD Research a cutting edge that has lead to tremendous, triple-figure percentage growth over the past two years. iCD Research is headquartered in London, with operational offices in the US and Australia to ensure that it is offering an unparalleled 24 hour service to its clients.